Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06203327

Atrophic Gastritis Predicts the Risk of Gastric Cancer

Despite declining incidence rates, gastric cancer (GC) ranks the fourth leading cause of cancer-related mortality and the fifth most common cancer worldwide, with the highest incidence reported in Eastern Asia. The 5-year overall survival rate of early GC exceeds 90%, which was well above advanced GC. Most intestinal-type GCs follow the Correa cascade-inflammation,atrophy, intestinal metaplasia (IM), dysplasia and subsequent carcinoma. The presence of gastric mucosal atrophy and intestinal metaplasia are important risk factors for GC. The purpose of this study was to investigate the incidence of GC attributed to atrophic gastritis in a region with high incidence of GC.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Atrophic Gastritis Digestive System Diseases Digestive System Neoplasms Gastritis Gastritis, Atrophic Gastroenteritis Gastrointestinal Diseases Gastrointestinal Neoplasms Neoplasms Neoplasms by Site Stomach Diseases Stomach Neoplasms

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Renji Hospital, School of Medicine, Shanghai Jiao Tong University

Shanghai, Shanghai Municipality, 200127, China

Location status: Recruiting

Location contact

Hong Lu, M.D.,Ph.D

CONTACT

Jinnan Chen, M.M.

CONTACT

Xiao Liang, M.D.,Ph.D

CONTACT

Yixian Guo, M.M.

CONTACT

Yu Huang, M.M.

CONTACT

[email protected]

86+18621791879

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Ability and willingness to participate in the study and to sign and give informed consent
  • Biopsies were collected based on the recommendation of updated Sydney system

Exclusion criteria

  • under 18 or over 80 years old
  • history of gastrectomy
  • severe systemic diseases or malignancy

Treatment and study plan

Esophagogastroscopy (OLGA 0-Ⅰ)

Other

Surveillance endoscopies at years 3-5.

Esophagogastroscopy (OLGA II)

Other

Surveillance endoscopies at years 2-3.

Esophagogastroscopy (OLGA III-IV)

Other

Surveillance endoscopies every year.

Primary outcomes

  1. early gastric neoplasm

    Time frame: After the baseline endoscopy, participants were scheduled for surveillance endoscopies at years 3-5 for subjects with operative link on gastritis assessment (OLGA) 0-Ⅰ, at years 2-3 for subjects with OLGA II and 1 year for subjects with OLGA III-IV.

    histological diagnosis of high-grade dysplasia, and adenocarcinoma.

Sponsors and collaborators

Lead sponsor

Shanghai Jiao Tong University School of Medicine

Other

Registry information

Official study title

Atrophic Gastritis Predicts the Risk of Gastric Cancer: a Prospective Cohort Study

Important dates

Study start
2023
Primary completion
2034
Study completion
2034
First posted
Jan 12, 2024
Registry last updated
Dec 30, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.